	Application No.	Applicant(s)
Notice of Allowability	09/491,982	SHAUGHNESSY ET AL.
	Examiner	Art Unit
	Prema M. Mertz	1646
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT F of the Office or upon petition by the applicant. See 37 CFR 1.31	S (OR REMAINS) CLOSED in this i) or other appropriate communica RIGHTS. This application is subje	s application. If not included ation will be mailed in due course. THIS
1. This communication is responsive to the amendment filed	<u>1 3/21/2005</u> .	
2. The allowed claim(s) is/are 1, 3, 14, 43-50, renumbered,	1, 2, 3, 4-11, respectively.	v
3. \boxtimes The drawings filed on <u>04 February 2002</u> are accepted by	the Examiner.	
 4. Acknowledgment is made of a claim for foreign priority of a) All b) Some* c) None of the: Certified copies of the priority documents have Certified copies of the priority documents have Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	re been received. re been received in Application No ocuments have been received in t	o. <u>09/314,152</u> . this national stage application from the
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDON! THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted.	MENT of this application. nitted. Note the attached EXAMIN	IER'S AMENDMENT or NOTICE OF
INFORMAL PATENT APPLICATION (PTO-152) which giv		laration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") mu		TO 048) attached
(a) ☐ including changes required by the Notice of Draftsper1) ☐ hereto or 2) ☐ to Paper No./Mail Date	•	10-946) attached
(b) ☐ including changes required by the attached Examiner Paper No./Mail Date	's Amendment / Comment or in th	
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in		
7. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Inform	al Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. 🗌 Interview Summ	nary (PTO-413),
Information Disclosure Statements (PTO-1449 or PTO/SB/ Paper No./Mail Date	Paper No./Mail 08), 7. ☐ Examiner's Ame	
4. Examiner's Comment Regarding Requirement for Deposit		ement of Reasons for Allowance
of Biological Material	9.	
		PREMA MERTZ PREMARY EXAMINER

Application/Control Number: 09/491,982

Art Unit: 1646

€ . . .

- 1. Claims 1, 3, 14, 43-50 are allowable and have been renumbered 1, 2, 3, 4-11, respectively.
- 2. The declaration by Stephen Shaughnessy under 37 CFR § 1.132 submitted on 3/21/2005 is persuasive and sufficient to overcome the 35 USC § 103(a) rejections of claims 1, 3, 14, 43-49 as being unpatentable over Girasole et al. in view of Kishimoto et al. (U.S. Pat. No. 5,888,5100) and claim 50 as being unpatentable over Girasole et al (1995) in view of Kishimoto et al. (US Patent No. 5,888,510) as applied to claims 1, 3, 14, 43-49 above, and further in view of Queen et al. (US Patent No. 5,530,101) because of the showing in the declaration that the activities of osteoclast and osteoblast though complementary are not balanced in the sense of a see-saw where, when one goes up, the other goes down. For example, the references by Wronski et al (1985, 1986, 1988) provided in the declaration demonstrate that ovariectomization results in an increase in both resorption and bone formation. Therefore, the submitted declaration is sufficient to overcome the standing 35 USC § 103(a) rejections of claims 1, 3, 14, 43-50.
- 3. The following is an Examiner's Statement of Reasons for Allowance:

None of the prior art of record describe or suggest a method for the treatment of a clinical condition comprising increased bone resorption or decreased bone formation, the method comprising administering to said patient an effective amount of an anti-IL-11 antibody, which inhibits the formation of a tertiary complex of Interleukin-11 (IL-11), Interleukin-11 receptor (IL-11R), and glycoprotein 130 (gp130), to increase osteoblast-mediated bone formation and to decrease osteoclast-mediated bone resorption.

Application/Control Number: 09/491,982 Page 3

Art Unit: 1646

4. Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably **accompany** the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (571) 272-0829.

Official papers filed by fax should be directed to (571) 273-8300. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prema Mertz Ph.D. Primary Examiner Art Unit 1646 April 14, 2005